An Efficacy and Outcome Study of Supplemental Oxygen Treatment in Patients With Suspected Myocardial Infarction (DETO2X-AMI)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01787110 |
Recruitment Status :
Completed
First Posted : February 8, 2013
Last Update Posted : December 11, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The use of supplemental oxygen in the setting of suspected acute myocardial infarction (AMI) is manifested in international treatment guidelines and established in prehospital and hospital clinical routine throughout the world.
However, to date there is no conclusive evidence from adequately designed and powered trials supporting this practice. Existing data is conflicting and failing to clarify the role of supplemental oxygen in AMI.
The DETO2X-AMI trial is designed to shed light on this important issue.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Coronary Syndrome Non-ST Elevation (NSTEMI) Myocardial Infarction Acute ST Segment Elevation Myocardial Infarction Angina, Unstable | Drug: Oxygen | Phase 3 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 6629 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | DETermination of the Role of OXygen in Suspected Acute Myocardial Infarction (DETO2X-AMI) Based on the SWEDEHEART Registry |
Actual Study Start Date : | April 2013 |
Actual Primary Completion Date : | December 30, 2016 |
Actual Study Completion Date : | December 30, 2016 |

Arm | Intervention/treatment |
---|---|
No Intervention: No oxygen
For patients randomised to withholding oxygen treatment
|
|
Active Comparator: Oxygen
For patients randomised to oxygen therapy:
|
Drug: Oxygen
see arm description |
- 1-year all-cause mortality [ Time Frame: 1 year ]1-year all-cause mortality on an intention to treat basis (ITT)
- MACE 1 [ Time Frame: 1 year ]All-cause mortality or rehospitalization with heart failure at 1-year
- MACE 2 [ Time Frame: 1 year ]All-cause mortality or rehospitalization with heart failure or readmission with myocardial infarction at 1-year
- STEMI-PCI-MACE [ Time Frame: 1 year ]All-cause death or rehospitalization with MI or cardiogenic shock or stent thrombosis at one year
- Rehospitalization with heart failure [ Time Frame: 1 year ]Rehospitalization with heart failure at 1-year
- Rehospitalization with AMI [ Time Frame: 1 year ]Rehospitalization with AMI at 1-year
- Rehospitalization with shock (Killip ≥3) [ Time Frame: 1 year ]Rehospitalization with shock (Killip ≥3) at 1-year
- Cardiovascular death [ Time Frame: 1 year ]Cardiovascular death at 1-year
- Health economics [ Time Frame: 1 year ]Health economics concerning supplemental oxygen treatment from prehospital contact of the emergency service, hospital stay until follow-up 1 year in patients with AMI below 75 years of age

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 30 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- symptoms (chest pain, dyspnea) indicating acute myocardial ischemia within the last 6 hours
- ECG changes (ST-segment elevation ≥ 2 mm V1-V4, or ≥ 1 mm in other leads, ST-segment depression >1 mm in any lead, negative T-wave in leads V2-V6, pathological Q-wave in at least 2 adjacent leads), left bundle branch block
and/or elevated levels of cardiac troponin levels in the ED
indicating acute myocardial ischemia
- oxygen saturation ≥90% (pulse oximeter)
- age ≥30
Exclusion Criteria:
- unwillingness to participate
- inability to comprehend given information
- continuous oxygen delivery at home prior to inclusion
- cardiac arrest prior to inclusion

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01787110

Study Director: | Leif Svensson, MD, PHD | Karolinska Institutet |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Leif Svensson, Professor of Cardiology, Karolinska Institutet |
ClinicalTrials.gov Identifier: | NCT01787110 |
Other Study ID Numbers: |
DETO2X-AMI 2012/287-12 |
First Posted: | February 8, 2013 Key Record Dates |
Last Update Posted: | December 11, 2017 |
Last Verified: | March 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Acute coronary syndrome Acute myocardial infarction Non ST-segment Myocardial Infarction ST-segment Myocardial Infarction Oxygen STEMI NSTEMI |
Unstable angina Randomised trial CMR Mortality RCRT RRCT |
Myocardial Infarction Acute Coronary Syndrome ST Elevation Myocardial Infarction Infarction Myocardial Ischemia Angina, Unstable Pathologic Processes Ischemia |
Necrosis Heart Diseases Cardiovascular Diseases Vascular Diseases Angina Pectoris Chest Pain Pain Neurologic Manifestations |